ライフサイエンスコーパス: trachomatis

1 itive for T. vaginalis (P < 0.0002 versus C. trachomatis).

2 lopmentally controlled ompA expression in C. trachomatis.

3 he development of specific treatments for C. trachomatis.

4 tubal infertility in women infected with C. trachomatis.

5 n situ at the late developmental cycle of C. trachomatis.

6 protection against genital infection with C. trachomatis.

7 f antibodies in protection against Chlamydia trachomatis.

8 pressing a FLAG-tagged version of IncD in C. trachomatis.

9 te CtFabI as a therapeutic target against C. trachomatis.

10 he obligate intracellular bacteria Chlamydia trachomatis.

11 subversion of cellular innate immunity by C. trachomatis.

12 ence of circulating genomic resistance in C. trachomatis.

13 is probably longer than for NGU caused by C. trachomatis.

14 mission is probably lower than for Chlamydia trachomatis.

15 r investigating the human pathogen Chlamydia trachomatis.

16 seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%).

17 In the class I-c beta subunit from Chlamydia trachomatis, a heterodinuclear Mn(II)/Fe(II) complex rea

18 Chlamydia trachomatis, a leading bacterial cause of sexually trans

19 fication tests (NAATs) that detect Chlamydia trachomatis AC2 also detects Neisseria gonorrhoeae Stora

20 . muridarum and the human pathogen Chlamydia trachomatis activate not only NLRP3 but also AIM2.

21 to elucidate the mechanism that controls C. trachomatis adaptability.

22 alence and factors associated with rectal C. trachomatis among female sexually transmitted infection

23 nd changes in sexual behaviors and Chlamydia trachomatis, an infection with similar epidemiology to a

24 ysis were vaccine status, positive Chlamydia trachomatis and >/=4 partners in the preceding year.

25 of 300 colony forming units (CFU)/mL for C. trachomatis and 1500CFU/mL for N. gonorrhoeae.

26 n 9 of 11 (82%) participants positive for C. trachomatis and 7 of 10 (70%) participants positive for

27 Lower genital tract infection with Chlamydia trachomatis and C. muridarum can induce long-lasting hyd

28 Plasmid-free Chlamydia trachomatis and Chlamydia muridarum fail to induce sever

29 Chlamydia trachomatis and Mycoplasma genitalium coinfections were

30 up to 84 days and (ii) swabs seeded with C. trachomatis and N. gonorrhoeae and then placed in transp

31 pheid Xpert CT/NG assay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharyngeal

32 ns were significantly more prevalent than C. trachomatis and N. gonorrhoeae infections, while the M.

33 rtility and ectopic pregnancy, and Chlamydia trachomatis and Neisseria gonorrhoeae are recognized mic

34 is the preferred method to detect Chlamydia trachomatis and Neisseria gonorrhoeae, but no commercial

35 ociations, which parallel those of Chlamydia trachomatis and Neisseria gonorrhoeae, the mechanisms by

36 most common bacterial infections: Chlamydia trachomatis and Neisseria gonorrhoeae.

37 ig-tailed macaques inoculated with Chlamydia trachomatis and Trichomonas vaginalis (n = 9) or medium

38 ether coinfection of macaques with Chlamydia trachomatis and Trichomonas vaginalis decreases the prop

39 testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis were performed.

40 of the proportion of PID cases caused by C. trachomatis are 35% (95% credible interval [CrI], 11%-69

41 ugh most individuals infected with Chlamydia trachomatis are initially asymptomatic, symptoms can ari

42 to obtain these electron carriers within C. trachomatis are poorly understood.

43 e intracellular bacterial parasite Chlamydia trachomatis are the same as its eukaryotic host except t

44 Neisseria gonorrhoeae and Chlamydia trachomatis are well-documented urethral pathogens, and

45 C. trachomatis assembles its membrane systems from the uniq

46 to the genetically intractable status of C. trachomatis at that time, this model of IncD-CERT intera

47 The infectious load of C. trachomatis before MDA was determined in 30 children who

48 this experimental approach revealed that C. trachomatis broadly alters host proteins and can be appl

49 xert their effector function and decrease C. trachomatis burden.

50 n of chlamydia might have been exposed to C. trachomatis but not infected.

51 s (NGU) and cervicitis is aimed at Chlamydia trachomatis, but Mycoplasma genitalium, which also commo

52 We recently detected PG in Chlamydia trachomatis by a new metabolic cell wall labeling method

53 the membrane of the human pathogen Chlamydia trachomatis (C.t.).

54 Chlamydia trachomatis can enter a viable but nonculturable state i

55 Ocular infection with Chlamydia trachomatis can lead to trachoma, a leading infectious c

56 fecal-oral route; (2) in the modern era, C. trachomatis causes "opportunistic" infection at non-GI s

57 Chlamydia trachomatis causes both trachoma and sexually transmitte

58 Chlamydia trachomatis causes sexually transmitted infections and t

59 mptoms is used to manage anorectal Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonor

60 s the CD8(+) T cell response and enhances C. trachomatis clearance.

61 with monoinfections with M. genitalium or C. trachomatis compared to women with no detectable STIs.

62 om patients with symptoms consistent with C. trachomatis conjunctivitis and with previously demonstra

63 Chlamydia trachomatis conjunctivitis may present with extended sym

64 For appropriate therapy, C. trachomatis conjunctivitis should be diagnosed definitiv

65 pholipid molecular species synthesized by C. trachomatis contained oleic acid, an abundant host fatty

66 ther with the intriguing observation that C. trachomatis CopN does not bind tubulin, our data support

67 Chlamydia trachomatis (Ct) has been associated with miscarriage bu

68 he obligate-intracellular pathogen Chlamydia trachomatis (Ct) has undergone considerable genome reduc

69 is and management of uncomplicated Chlamydia trachomatis (CT) infection in adolescents and adults tha

70 Genital Chlamydia trachomatis (Ct) infection induces protective immunity t

71 The frequency and duration of Chlamydia trachomatis (Ct) ocular infections decrease with age, su

72 V, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the

73 t allows simultaneous detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and an int

74 An example is infection with Chlamydia trachomatis (Ct), which is the most common sexually tran

75 We tested 30 potentially Chlamydia trachomatis (CT)-infected patients in a hospital emergen

76 for Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT).

77 Trachoma is caused by Chlamydia trachomatis (Ct).

78 ted HLA-DR4 transgenic mice with 5 x 10(5)C. trachomatis D inclusion forming units (IFU) induced a si

79 were more susceptible to a transcervical C. trachomatis D infection than WT mice.

80 be protected by vaccination, 10(4) IFU of C. trachomatis D was delivered intranasally, and mice were

81 cally 6 weeks later with 5 x 10(5) IFU of C. trachomatis D.

82 The PEFs of PID due to C. trachomatis decline steeply with age by a factor of arou

83 ate intracellular bacteria such as Chlamydia trachomatis depend on metabolites of the host cell and t

84 dded to the medium were incorporated into C. trachomatis-derived phospholipid molecular species.

85 to investigate the epidemiology of repeat C. trachomatis detection after treatment in C. trachomatis-

86 ol in understanding the origins of repeat C. trachomatis detection after treatment.

87 Repeat Chlamydia trachomatis detection frequently occurs within months af

88 MA (12,999 specimens) on the basis of the C. trachomatis detection rate, specimen source distribution

89 in those with versus those without repeat C. trachomatis detection.

90 Our study demonstrates that most repeat C. trachomatis detections after treatment were new infectio

91 aginal squamous epithelial cells, whereas C. trachomatis did not.

92 lymerase chain reaction [PCR] results for C. trachomatis DNA by Roche Amplicor) and 25 true-negative

93 previously proposed that insertion of the C. trachomatis effector protein IncD into the inclusion mem

94 resented here show that expression of the C. trachomatis effector protein IncD mediates the recruitme

95 Chlamydia trachomatis elementary body enzyme-linked immunosorbent

96 chemical analysis established the role of C. trachomatis-encoded acyltransferases in producing the ne

97 mannii, Burkholderia pseudomallei, Chlamydia trachomatis, Escherichia coli, Klebsiella pneumoniae, Le

98 al fragmentation prevented replication of C. trachomatis even in p53-deficient cells.

99 latives, the oculogenital pathogen Chlamydia trachomatis evolved as a commensal organism of the human

100 comparison, mice vaginally infected with C. trachomatis exhibited transient low-burden infections, p

101 Chlamydia trachomatis exits host epithelial cells through two equa

102 The C. trachomatis FabI (CtFabI) is a homotetramer and exhibite

103 n of Cdu1 led to increased sensitivity of C. trachomatis for IFNgamma and impaired infection in mice.

104 ction of Neisseria gonorrhoeae and Chlamydia trachomatis from pharyngeal and rectal specimens among p

105 on of reproductive damage attributable to C. trachomatis Further studies using modern assays in conte

106 enetics to evaluate the contribution of a C. trachomatis gene to disease pathogenesis.

107 findings and to advance understanding of C. trachomatis genetic expression.

108 Chlamydia trachomatis genital tract infection is a major cause of

109 olates appear to be recombinants with UGT C. trachomatis genome backbones, in which loci that encode

110 The human pathogen Chlamydia trachomatis grows in a glycogen-rich vacuole.

111 , and Neisseria gonorrhoeae and/or Chlamydia trachomatis had 92% lower odds of any adverse birth outc

112 he obligate intracellular parasite Chlamydia trachomatis has a reduced genome and is thought to rely

113 he obligate intracellular parasite Chlamydia trachomatis has a reduced genome but relies on de novo f

114 C. trachomatis has adjacent genes encoding the separate dom

115 In this work, we are showing that C. trachomatis has an active respiratory metabolism that se

116 For decades C. trachomatis has been considered an "energy parasite" tha

117 id of both Chlamydia muridarum and Chlamydia trachomatis has been shown to control virulence and infe

118 We show that a LipL2 enzyme from Chlamydia trachomatis has similar activity, demonstrating conserva

119 ins of the intracellular bacterium Chlamydia trachomatis have been associated with immune pathology a

120 sed to predict up to 59 putative Incs for C. trachomatis; however, localization to the inclusion memb

121 The 1.58A crystal structure of C. trachomatis hypothetical protein CT263 presented here su

122 ection induces partial immunity to Chlamydia trachomatis Identification of chlamydial antigens that i

123 support the full infectious life cycle of C. trachomatis in a manner that mimics the infection of hum

124 epeated episodes of infection with Chlamydia trachomatis in childhood lead to severe conjunctival inf

125 ng the potential role of gastrointestinal C. trachomatis in human chlamydial pathogenesis.

126 pseudotuberculosis and also secreted from C. trachomatis in infected cells where it localizes appropr

127 The detection of C. trachomatis in ocular specimens by NAAT was verified for

128 ntributing to the increased prevalence of C. trachomatis in the human GI tract.

129 voids the characteristic low virulence of C. trachomatis in the mouse, we previously demonstrated a s

130 a) resistance of C. muridarum compared to C. trachomatis in the murine genital tract.

131 ize the mucosal CD8(+) T cell response to C. trachomatis in the murine genital tract.

132 genetically intransigent pathogen Chlamydia trachomatis, in which all mutations have been identified

133 of Inc function(s), we subjected putative C. trachomatis Incs to affinity purification-mass spectrosc

134 NOD2-dependent activation of NF-kappaB by C. trachomatis-infected cell lysates as a biomarker for the

135 major suppressor of metabolite supply in C. trachomatis-infected cells.

136 ; P < 0.0001) and higher than that of the C. trachomatis-infected females (mean, 23.8 years; P = 0.00

137 AFN-1252 treatment of C. trachomatis-infected HeLa cells at any point in the infe

138 (miRNAs) in maintaining the viability of C. trachomatis-infected primary human cells.

139 trachomatis detection after treatment in C. trachomatis-infected subjects seen at a sexually transmi

140 r successful CD4(+) T cell trafficking to C. trachomatis-infected tissues, we will be better equipped

141 hat CVM was significantly associated with C. trachomatis infection (odds ratio [OR], 4.2 [95% confide

142 Women who tested positive for Chlamydia trachomatis infection after having been contact-traced b

143 , which replicates many features of human C. trachomatis infection and avoids the characteristic low

144 directs IFN-beta expression during Chlamydia trachomatis infection and suggest that effectors from in

145 ns of trachomatous inflammation or Chlamydia trachomatis infection diagnosed using PCR.

146 ucosa protective immunity against genital C. trachomatis infection following intranasal immunization

147 rge to diagnose N. gonorrhoeae and Chlamydia trachomatis infection in certain populations by nucleic

148 CD4(+) T cell-mediated protection against C. trachomatis infection in the genital mucosa.

149 Chlamydia trachomatis infection in the lower genital tract can asc

150 Finally, C. trachomatis infection interferes with the SNX5:CI-MPR in

151 The role of organism load in Chlamydia trachomatis infection is not well understood.

152 Chlamydia trachomatis infection is the most common bacterial sexua

153 Chlamydia trachomatis infection is the most common sexually transm

154 Primary C. trachomatis infection of mice also causes no genital pat

155 r memory CD8(+) T cell development during C. trachomatis infection of mice.

156 In this study, we demonstrate that C. trachomatis infection of the upper genital tract results

157 Urogenital Chlamydia trachomatis infection remains prevalent and causes subst

158 ion frequently occurs within months after C. trachomatis infection treatment.

159 Characteristics associating with C. trachomatis infection were examined using bivariable and

160 % confidence interval {CI}, .20-1.23] for C. trachomatis infection, 0.56 [95% CI, .19-1.67] for N. go

161 be significantly associated with TF/TI or C. trachomatis infection, and the use of sanitation facilit

162 es in a murine model of intranasal Chlamydia trachomatis infection, we analogously found that LNG tre

163 omen notified by a sex partner for Chlamydia trachomatis infection.

164 vides another target for agents to combat C. trachomatis infection.

165 th pathological sequelae of ocular Chlamydia trachomatis infections in The Gambia.

166 Genital Chlamydia trachomatis infections in women typically are asymptomat

167 Currently, a vaccine to prevent C. trachomatis infections is not available.

168 ement a vaccine to protect against Chlamydia trachomatis infections.

169 , is unable to protect against subsequent C. trachomatis infections.

170 o thiazolino 2-pyridones which attenuated C. trachomatis infectivity without affecting host cell or c

171 y, we show that the human pathogen Chlamydia trachomatis infects the murine respiratory and genital m

172 ), and IL-4Ralpha(-/-) mice with low-dose C. trachomatis inoculums.

173 The bacterial pathogen Chlamydia trachomatis is a global health burden currently treated

174 Chlamydia trachomatis is a global health burden due to its prevale

175 Chlamydia trachomatis is a leading cause of genital and ocular inf

176 Plasmid-free C. trachomatis is also attenuated in both the mouse genital

177 Chlamydia trachomatis is an important human pathogen that undergoe

178 Chlamydia trachomatis is an important risk factor for PID, but the

179 Chlamydia trachomatis is an obligate intracellular epitheliotropic

180 Chlamydia trachomatis is an obligate intracellular human pathogen

181 Chlamydia trachomatis is an obligate intracellular human pathogen

182 Chlamydia trachomatis is an obligate intracellular mucosotropic pa

183 Chlamydia trachomatis is an obligate intracellular pathogen that r

184 Chlamydia trachomatis is an obligate intracellular pathogen that r

185 Chlamydia trachomatis is an obligate intracellular pathogen that r

186 Genomic analysis predicts that C. trachomatis is capable of type II fatty acid synthesis (

187 long-term infections of humans by Chlamydia trachomatis is poorly understood.

188 igate intracellular human pathogen Chlamydia trachomatis is the etiological agent of blinding trachom

189 Chlamydia trachomatis is the leading cause of infection-induced in

190 e obligate intracellular bacterium Chlamydia trachomatis is the most common cause of bacterial sexual

191 Chlamydia trachomatis is the most common notifiable disease in Can

192 Chlamydia trachomatis is the world's most prevalent bacterial sexu

193 but the proportion of PID cases caused by C. trachomatis is unclear.

194 he obligate intracellular organism Chlamydia trachomatis, is the world's leading cause of preventable

195 Host sphingomyelin was associated with C. trachomatis isolated by detergent extraction, but it may

196 nducted whole-genome sequence analysis on C. trachomatis isolates collected from a previously describ

197 port the whole-genome sequences of ocular C. trachomatis isolates obtained from young children with c

198 Chlamydia trachomatis isolates that cause trachoma, sexually trans

199 Chlamydia trachomatis isolates were obtained before and after MDA

200 he complete deletion of specific genes in C. trachomatis L2.

201 Repeated infections with C. trachomatis lead to serious sequelae, such as infertilit

202 l assays, we observed that infection with C. trachomatis led to downregulated expression of inducible

203 Plasmid copy number, C. trachomatis load and disease severity were assessed in a

204 18]) and there were no associations with C. trachomatis load or disease severity.

205 The VD4 region from the Chlamydia trachomatis major outer membrane protein contains import

206 tive predictive values for M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 100,

207 Incidence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection)

208 52 tested C. trachomatis positive and 41 C. trachomatis negative.

209 he intervention effect on incident Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genit

210 e tested for M. genitalium and for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vagi

211 valences of Mycoplasma genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vagi

212 st-void female urine specimens for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vagi

213 ghts concerning the concurrence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitaliu

214 nk alcohol and to be infected with Chlamydia trachomatis, Neisseria gonorrhoeae, or herpes simplex vi

215 enitalium and other STI organisms (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginali

216 For C. trachomatis, neither system was >95% sensitive from the

217 adation in the AC2 assay for detection of C. trachomatis or N. gonorrhoeae was observed, although som

218 ifferent urine samples spiked with either C. trachomatis or N. gonorrhoeae, and also containing both

219 eported recent sexual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an STI

220 n testing would detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is no U

221 review to investigate the epidemiology of C. trachomatis organism load in human genital chlamydia inf

222 The exploitation of genetically labeled C. trachomatis organisms with P3-driven GFP allows for the

223 n that of SOC testing (96%) for detecting C. trachomatis (P = 0.167).

224 methods did not differ significantly for C. trachomatis (P = 0.774) or N. gonorrhoeae (P = 0.163).

225 In this review, we revisit C. trachomatis pathogenesis data from mice and humans using

226 tion, a model that has been used to study C. trachomatis pathogenesis in women, is known to depend on

227 darum, a model pathogen for investigating C. trachomatis pathogenesis, readily spreads from the mouse

228 A common feature of C. trachomatis persistence models is that reticulate bodies

229 We now report that C. trachomatis Pgp3 can neutralize the antichlamydial activ

230 er paper to test for antibodies to Chlamydia trachomatis pgp3 using a multiplex bead assay.

231 ead being placed within UGT clades of the C. trachomatis phylogenetic tree.

232 Current data on C. trachomatis phylogeny show that there is only a single t

233 The Chlamydia trachomatis plasmid is a virulence factor.

234 g of human epithelial cells infected with C. trachomatis plasmid-bearing (A2497) and plasmid-deficien

235 The C. trachomatis polymorphic membrane protein D (PmpD) is a h

236 acterized for 93 women, of whom 52 tested C. trachomatis positive and 41 C. trachomatis negative.

237 luded 98 women who were contact-traced by C. trachomatis-positive sex partners at the STI outpatient

238 OmpA genotyping was performed on C. trachomatis-positive urogenital specimens obtained from

239 confidence interval [CI], 9.5%-24.0%) and C. trachomatis prevalence was 14.7% (95% CI, 7.8%-21.6%) in

240 acids were incorporated exclusively into C. trachomatis-produced phospholipid molecular species.

241 Our results indicate that C. trachomatis profoundly remodels the host proteome indepe

242 rate that FASII activity is essential for C. trachomatis proliferation within its eukaryotic host and

243 udy the development-dependent function of C. trachomatis promoters in an attempt to elucidate the mec

244 arator assays included BD ProbeTec Chlamydia trachomatis Q(x) (CTQ)/Neisseria gonorrhoeae Q(x) (GCQ),

245 bound intracellular niche, the inclusion, C. trachomatis relies on a set of effector proteins that ar

246 Chlamydia trachomatis remains a leading cause of bacterial sexuall

247 Obligate intracellular Chlamydia trachomatis replicate in a membrane-bound vacuole called

248 Additionally, C. trachomatis replication depends on a subset of altered p

249 We show that C. trachomatis require mitochondrial ATP for normal develop

250 Upon entry into host cells, C. trachomatis resides within a membrane-bound compartment-

251 The genomic data suggest that C. trachomatis respiratory chain could produce a sodium gra

252 be Aptima Combo 2 assay) for detection of C. trachomatis ribosomal RNA (rRNA) from direct ocular samp

253 transport medium (n = 5) were tested for C. trachomatis rRNA by NAAT.

254 ys, respectively) in two studies: (i) dry C. trachomatis-seeded swabs were used with ACT after storag

255 ns that can be applied to humans, we used C. trachomatis serovar D (strain UW-3/Cx) to induce inferti

256 region verifies that P3 is a new class of C. trachomatis sigma(66)-dependent promoter, which requires

257 rent chemokine receptors are critical for C. trachomatis-specific CD4(+) T cells to home to the lung,

258 The 25 C. trachomatis specimens with PCR-positive results (obtaine

259 ithin a few days, while a CPAF-sufficient C. trachomatis strain (L2-5) survived in the lower genital

260 We now report that a Chlamydia trachomatis strain deficient in expression of CPAF (L2-1

261 ment were new infections with a different C. trachomatis strain rather than reinfection with the same

262 C. trachomatis strains can be differentiated by sequencing

263 Genital C. trachomatis strains can counter tryptophan limitation be

264 , we screened a population of mutagenized C. trachomatis strains for mutants that failed to reactivat

265 Of the 35 subjects with C. trachomatis strains genotyped at enrollment and follow-u

266 ed more often in subjects with discordant C. trachomatis strains than in those with concordant strain

267 Half of the subjects with discordant C. trachomatis strains who reported sexual activity since t

268 r membrane protein A (OmpA) genotyping of C. trachomatis strains.

269 ated a critical role of CPAF in promoting C. trachomatis survival in the mouse lower genital tracts.

270 intact structure of the primordial Chlamydia trachomatis T3SS in the presence and absence of host mem

271 eduled for a 6-month follow-up for repeat C. trachomatis testing.

272 enetic transformation protocol for Chlamydia trachomatis that for the first time provides a platform

273 ata point to an AasC-dependent pathway in C. trachomatis that selectively scavenges host saturated fa

274 lity (TFI) that is attributable to Chlamydia trachomatis, the population excess fraction (PEF), can b

275 the agent of oculogenital disease Chlamydia trachomatis, the respiratory pathogen C. pneumoniae, and

276 comparison to a 6-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of the C

277 ected with Chlamydia muridarum and Chlamydia trachomatis to determine if there were differences betwe

278 -acyl carrier protein reductase (FabI) of C. trachomatis to determine whether chlamydial FASII is ess

279 he potential for plasmid-deficient Chlamydia trachomatis to serve as a live attenuated vaccine in the

280 rified and analyzed three putative Chlamydia trachomatis topoisomerases.

281 Subjects were enrolled, tested for C. trachomatis, treated with azithromycin, and scheduled fo

282 mmon Ag in Chlamydia muridarum and Chlamydia trachomatis Using an adoptive-transfer approach, we show

283 les) for Neisseria gonorrhoeae and Chlamydia trachomatis using nucleic acid amplification tests detec

284 nal intercourse, were screened for rectal C. trachomatis using the Gen-Probe Aptima COMBO 2 Assay.

285 ion excess fractions (PEFs) of PID due to C. trachomatis, using routine data, surveys, case-control s

286 Our results indicate that C. trachomatis utilizes functionally diverse genes to media

287 lthough several lines of evidence suggest C. trachomatis utilizes host phospholipids, the bacterium e

288 ansgenic mouse model for evaluating human C. trachomatis vaccine antigens are discussed.

289 karyotic host cell is required for Chlamydia trachomatis virulence.

290 C. trachomatis was detected at follow-up in 39 subjects (24

291 C. trachomatis was detected from 59 rectal swabs and 8 phar

292 ity with a high prevalence of STI, Chlamydia trachomatis was detected in 8.7% and Neisseria gonorrhoe

293 lopments in the genetic transformation in C. trachomatis, we constructed a versatile green fluorescen

294 The enrollment visit OmpA genotypes for C. trachomatis were determined for 162 subjects (92% female

295 Replicating Chlamydia trachomatis were labelled with these probes throughout t

296 species associated with human disease are C. trachomatis, which is the leading cause of both reportab

297 cans, Streptococcus agalactiae and Chlamydia trachomatis with a single biochip, enabling a quick scre

298 darum, a murine model of human urogenital C. trachomatis, with severely attenuated disease developmen

299 g infectivity across multiple serovars of C. trachomatis without host cell toxicity.

300 For C. trachomatis, Xpert was 95% sensitive (95% CI, 86 to 99%)